Checkpoint inhibitors in AML: Are we there yet? Review
| Authors: | Ghosh, A.; Barba, P.; Perales, M. A. |
| Review Title: | Checkpoint inhibitors in AML: Are we there yet? |
| Abstract: | Immunotherapy is distinct from traditional chemotherapy in that it acts on immune cells rather than cancer cells themselves. Monoclonal antibodies targeting immune checkpoints on T cells – CTLA-4 and PD-1 – and PD-L1 on the cells of immune microenvironment are now approved for clinical use in several solid tumors and hematological malignancies. This article provides a general overview of the use of checkpoint inhibitors in hematologic malignancies with a special focus in acute myeloid leukemia. © 2019 British Society for Haematology and John Wiley & Sons Ltd |
| Keywords: | cancer chemotherapy; cancer survival; unclassified drug; review; drug safety; cytarabine; outcome assessment; high risk patient; hodgkin disease; gene expression regulation; lymphoma; allogeneic hematopoietic stem cell transplantation; idarubicin; ctla-4; funding; hla antigen; immunocompetent cell; protein inhibitor; pd-1; pd-l1; acute myeloid leukemia; nivolumab; pidilizumab; disease burden; human; priority journal; checkpoint inhibitor; pembrolizumab; whole exome sequencing; checkpoint inhibitors |
| Journal Title: | British Journal of Haematology |
| Volume: | 188 |
| Issue: | 1 |
| ISSN: | 0007-1048 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2020-01-01 |
| Start Page: | 159 |
| End Page: | 167 |
| Language: | English |
| DOI: | 10.1111/bjh.16358 |
| PUBMED: | 31808941 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work